Lilly’s Van Naarden: Nothing is off the table for dealmaking

Key Concepts

• Precision Medicine: Targeted therapies designed to treat specific genetic or molecular characteristics of a patient's cancer.
• Business Development (BD) Strategy: A two-pronged approach involving high-volume, early-stage, low-cost deals alongside targeted, late-stage, de-risked acquisitions.
• Oncology Portfolio: Eli Lilly’s second-largest business segment, focused on high-unmet-need areas like lung, breast, bladder, and ovarian cancers, as well as myeloma.
• Capital Allocation: The strategic reinvestment of profits from the weight-loss business (GLP-1s) into diverse therapeutic areas to fuel long-term growth.
• De-risking: The process of prioritizing assets that have already demonstrated clinical efficacy in human trials.

---

1. Oncology Strategy and Portfolio

Jake Van Naarden, Head of Eli Lilly Oncology, emphasizes that the company is aggressively targeting the most significant challenges in cancer care. While recent data presentations included rare forms of lung cancer, the broader portfolio focuses on high-prevalence indications:

• Key Assets:
  • Jaypirca: A medicine for chronic leukemia, representing one of the largest pharmaceutical classes.
  • Jaypirca/Inlurio: A newly launched breast cancer treatment with upcoming studies targeting early-stage breast cancer, the most common global cancer diagnosis.
  • Myeloma Program: A new initiative involving immune system reprogramming to target cancer cells.
• Growth Outlook: Lilly has a "line of sight" to eight new cancer medicines or major label expansions. Van Naarden notes that while the weight-loss business currently dominates investor attention, oncology remains the company's second-largest business and is poised for significant future expansion.

2. Business Development Framework

Van Naarden, who also serves as Head of Corporate Development, describes a deliberate, two-pronged strategy for acquisitions:

• Prong 1 (Early-Stage): A high volume of low-cost, early-stage deals. These are inherently risky, but the goal is for the successful candidates to provide significant value that offsets the cost of the entire portfolio.
• Prong 2 (Late-Stage/De-risked): Expanding the aperture to include assets with existing human clinical data. These are more expensive but offer higher certainty of success.
• Valuation Discipline: Lilly does not set arbitrary price caps on deals. Instead, they evaluate the "compelling nature of the science" and the potential patient impact. If a company’s valuation does not support long-term shareholder value, Lilly is willing to walk away.

3. Expansion into New Therapeutic Areas

Lilly is moving beyond its traditional four therapeutic buckets, signaling a broader interest in global public health:

• Infectious Disease/Vaccines: Despite being viewed as a "new" area, Van Naarden notes a historical precedent (e.g., polio vaccine). The company is re-entering this space to address pathogens that currently lack effective vaccines.
• Broadened Aperture: The company is actively evaluating opportunities that do not fit into their historical structure. Van Naarden stated, "There’s nothing off the table," provided the science is strong and the impact on patients is significant.

4. Notable Quotes

• "We have a really like almost generational opportunity to redeploy that capital in all of our disease areas to not only fuel growth for the company... but to help a lot more patients with all different kinds of diseases." — Jake Van Naarden on the impact of the company's current financial strength.
• "We don’t really set like arbitrary limits on size. It’s really about... how compelling is the science? How compelling is the patient opportunity?" — Jake Van Naarden on the criteria for large-scale acquisitions.

5. Synthesis and Conclusion

Eli Lilly is currently leveraging the massive financial success of its weight-loss franchise to aggressively diversify its oncology and broader medical portfolio. By balancing high-risk, early-stage innovation with strategic, de-risked late-stage acquisitions, the company aims to maintain long-term growth. The leadership is signaling a shift toward a more expansive, "no-limits" approach to therapeutic development, prioritizing clinical data and patient impact over rigid adherence to historical business segments. The core takeaway is that Lilly is positioning itself to be a dominant force in oncology and beyond, using its current capital surplus to secure a pipeline that will drive the company for decades.